The klow peptide is a multi-component research blend, commonly described as combining GHK-Cu, BPC-157, TB-500 and KPV in a single lyophilised vial. Each component is studied separately in laboratory work, for topics such as copper-dependent signalling, cytoskeletal dynamics, tissue-repair models and melanocortin-related anti-inflammatory pathways. The blend itself has no published research literature, which shapes how it should be understood and handled. This article describes the components, their proposed mechanisms, the research areas associated with each, and the analytical and storage standards that apply to a mixed peptide product. It is written for laboratory researchers and offers no guidance on human use.
What is klow peptide?
KLOW is a trade-style name rather than a recognised chemical entity. It does not appear in pharmacopoeias, and no regulator defines its composition. In the research supply market it usually refers to a fixed-ratio blend of four peptides, with the total vial content stated in milligrams. A common presentation totals 80 mg, made up of GHK-Cu, BPC-157, TB-500 and KPV in differing proportions. Because the name is not standardised, composition can differ between suppliers, and the product documentation should always be read in preference to the name.
The four components are chemically distinct. GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. The free tripeptide has a molecular weight of about 340 Da, and the copper complex is roughly 400 Da. It was identified in human plasma in the early 1970s by Loren Pickart and colleagues.
BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of about 1419 Da. It is described as a fragment of a larger “body protection compound” protein reported in gastric juice, and most of the published work on it comes from a single group of researchers in Zagreb, Croatia.
TB-500 is the name commonly used for a synthetic fragment of thymosin beta-4, a 43-residue protein of about 4.96 kDa found in most mammalian cells. Suppliers use “TB-500” for different sequences, and the most frequently described form is a short fragment containing the actin-binding motif Leu-Lys-Lys-Thr-Glu-Thr (LKKTET), which is far smaller than the full protein. This ambiguity matters, since results from full-length thymosin beta-4 cannot be assumed to apply to a fragment.
KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH). Its molecular weight is about 342 Da.
Because the klow peptide combines molecules with very different sizes and chemistries, characterising it is harder than characterising a single peptide. A researcher using the blend is effectively using four test articles at once, so any experiment must account for each one.
Mechanism of action
No mechanism has been established for the blend as a whole, so the sensible approach is to describe each component separately and to be clear that interactions between them have not been characterised in the literature.
GHK-Cu has no single defined receptor. Its proposed activity includes delivery of copper(II), an essential cofactor for enzymes such as lysyl oxidase and superoxide dismutase, together with reported effects on extracellular matrix synthesis and gene expression in cultured cells. Controls with copper salt alone and with GHK lacking copper are important, because some effects may reflect copper availability rather than a ligand-receptor interaction.
BPC-157 is reported in the primary literature to influence several signalling pathways, including nitric oxide signalling and growth factor receptor expression, and to modulate angiogenic markers in animal models. No single receptor has been conclusively identified, and independent replication outside the originating group is limited. Mechanistic statements should therefore be treated as provisional.
Thymosin beta-4 is a well-characterised actin-sequestering protein. It binds monomeric G-actin through the LKKTET region and so regulates the balance between monomeric and filamentous actin, which influences cell migration and cytoskeletal organisation. Extracellular roles have also been proposed. Whether a short synthetic fragment reproduces the full activities of the parent protein is a question the supplier literature rarely addresses.
KPV is proposed to act through pathways connected with inflammation. Studies in cell lines and mice have reported that it enters cells through the peptide transporter PepT1 and reduces activation of the transcription factor NF-kappaB and the production of pro-inflammatory cytokines. Because alpha-MSH acts on melanocortin receptors, some work has examined whether KPV signals through the same receptors, and the answer appears to depend on the model used.
Taken together, these components act through unrelated mechanisms, which is the reason that the blend cannot be treated as a single pharmacological entity.
What the research shows
The research literature relates to the individual components, and none of it was conducted with the klow peptide blend. Four areas are summarised below in general terms. Readers should consult the primary papers for methods, concentrations and statistics, because commercial summaries often overstate findings.
The first area is the original characterisation of GHK-Cu. Pickart and colleagues reported in the early 1970s that a tripeptide fraction from human plasma influenced the behaviour of hepatic cells in culture, and later chemical work established its sequence and copper affinity. Subsequent fibroblast culture studies examined collagen and glycosaminoglycan synthesis. These are cell biology observations. The foundational papers can be found through a PubMed search for the original GHK plasma isolation work.
The second area is thymosin beta-4 in animal wound models. Research groups, including work published around 1999 in rodents, reported that topical or systemic application of thymosin beta-4 altered measures such as wound contraction, re-epithelialisation and cell migration compared with controls. Exposures were expressed per kilogram of body weight or per wound, and values differ with route and formulation, so they should be taken from the primary papers. These were controlled animal experiments under ethical approval and are described here only as part of the scientific record. The topic can be explored through a PubMed search for thymosin beta-4 wound healing in animal models.
The third area is BPC-157 in rodent models. The Zagreb group has published a substantial series of papers describing the peptide in models of gastrointestinal injury, tendon and muscle injury and other experimental lesions, usually administered by injection or in drinking water at microgram-per-kilogram quantities. The consistency of positive findings across a narrow set of authors is itself a point that reviewers have raised, and independent replication would strengthen the evidence base. BPC-157 is not an authorised medicine in the United Kingdom, and it appears on the World Anti-Doping Agency prohibited list.
The fourth area is KPV in inflammation models. Studies in cultured intestinal epithelial cells and in mouse models of experimental colitis reported that KPV delivered to the gut reduced markers of inflammation, with a proposed role for PepT1-mediated uptake. These are rodent and cell-culture findings and carry no implication for any other setting.
A theme across these areas is that nothing in the literature tests the components together. Any claim that the blend produces a combined or synergistic effect is, at present, unsupported by published evidence, and researchers designing experiments should plan individual-component controls.
Research applications
In the laboratory, a mixed blend is used less often than its individual components, because mixtures make mechanistic attribution difficult. Where it is used, the contexts are generally exploratory.
One context is screening in cell culture, such as fibroblast, keratinocyte or epithelial cell models, where researchers examine migration, matrix synthesis or inflammatory marker expression. In this setting, comparing the blend against each component alone and against vehicle is essential to say anything about which constituent is responsible.
A second context is analytical method development. A four-component peptide mixture of very different masses is a useful test case for LC-MS methods that must resolve and quantify a tripeptide, a 15-mer and a larger fragment in one run. Reference blends also help laboratories develop screening methods for multi-peptide products.
A third context is stability and formulation research. Copper-containing complexes, histidine residues and short tripeptides behave differently in solution, and studies of how pH, buffer composition and co-solutes affect each component are directly relevant.
A fourth context is animal research on the individual components, which in the United Kingdom requires institutional ethical review and authorisation under the Animals (Scientific Procedures) Act 1986. Research peptides are not authorised medicines for human or veterinary use.
Purity, storage and handling
A mixed product raises the bar for quality control, because purity has to be shown for each component and not for the vial as a whole. Reversed-phase high-performance liquid chromatography (HPLC) with UV detection at 214 or 220 nm is the standard method, and a suitable gradient should resolve all four components. A single headline purity figure for a blend says little. The useful information is a chromatogram in which each component is identified, together with mass spectrometry confirmation of each expected mass: about 342 Da for KPV, about 340 Da (free) or 400 Da (copper complex) for GHK, about 1419 Da for BPC-157, and the stated mass of the TB-500 fragment. For the copper complex, evidence of copper content, from elemental analysis or ICP methods, adds a further check, since a peptide peak alone does not show that the complex formed.
A batch-specific certificate of analysis matters more for a blend than for a single peptide. It should carry a lot number matching the vial, the HPLC result, the observed and theoretical masses, the test date and the quantified amount of each component. Ratios in a blend can drift if mixing is imprecise, and net peptide content differs between components because of counterions and water. A stated total of 80 mg does not tell the researcher how much of each peptide is present.
Because the copper complex can dissociate in solution and the peptides may interact, batch-level verification matters more here than with a single, stable compound. UK laboratories sourcing the klow peptide should expect a batch-specific certificate of analysis with component-level data and lyophilised storage at -20°C, and the same documentation standard applies to buyers comparing Peptides UK- where to buy as a search term, since a supplier’s analytical record rather than its search ranking shows whether the vial matches its specification.
Lyophilised blends are generally stored at -20°C in a sealed container with desiccant, and -80°C is often used for long-term archives. Vials should reach room temperature before opening to prevent condensation on the cold powder. After reconstitution, stability falls. The solution should be divided into single-use aliquots and frozen, and repeated freeze-thaw cycles avoided. Short-term storage at 2 to 8°C is sometimes used, but the acceptable period should be validated for the assay, preferably by re-running HPLC on stored solutions. Buffers containing strong chelators such as EDTA can strip copper from GHK-Cu, and extremes of pH can accelerate deamidation and hydrolysis in the larger peptides.
Light and oxidation are secondary but real concerns. Copper can catalyse oxidation of susceptible residues, and aromatic and sulphur-containing side chains are vulnerable to photo-oxidation, so amber vials or dark storage are advisable. Low-bind tubes help prevent adsorption losses at low concentrations. A blue stock solution that changes colour is worth investigating before use.
Blend or individual vials?
A blend fixes the ratio between its components. Individual vials let each one be varied on its own. If the effect of any single component is a variable in the study, separate vials are the better choice. A blend suits work where the combination itself is what is being studied. Remember that the total milligrams in a blend vial do not tell you how much of any one component is present unless the ratio is stated on the certificate.
The components are also available separately: GHK-Cu, BPC-157, and the BPC-157 and TB-500 combination. For background on the individual peptides, see the GHK-Cu research hub and the BPC-157 research hub. For volume and concentration arithmetic when preparing stock solutions, use the peptide reconstitution calculator.
The UK position
None of the KLOW components is a licensed medicine in the UK, and none is approved for human consumption. Supply is for laboratory research only, with correct labelling. Blends carry an extra verification burden: the certificate of analysis should confirm the identity and purity of each component, not just the total mass in the vial. Our quality-standards SOP sets out the testing applied to every batch.
Frequently asked questions
What is klow peptide made of?
It is usually described as a blend of GHK-Cu, BPC-157, TB-500 and KPV, though the name is not standardised and composition can differ between suppliers. The batch certificate of analysis, not the product name, should be used to confirm which components and what quantities are present.
Has klow peptide been studied in published research?
No published studies appear to have examined the blend itself. Research exists on the individual components, mostly in cell culture and rodent models, and findings cannot be assumed to apply to the mixture. Any claim of combined effects lacks published support.
How should klow peptide be stored for research?
Keep lyophilised material at -20°C, or -80°C for long-term archiving, in a sealed, dry, light-protected container. Allow vials to reach room temperature before opening. After reconstitution, aliquot and freeze the solution, and avoid chelating buffers that can remove copper from GHK-Cu.
How can I verify the quality of a klow peptide batch?
Request a batch-specific certificate showing HPLC data and mass spectrometry confirmation for each component, plus quantified amounts and copper content, with a lot number matching the vial. For critical work, independent testing by an accredited analytical laboratory provides further assurance.
The klow peptide described in this article is supplied for in-vitro laboratory research only and is not intended for human or veterinary use.
For laboratory research use only.
Research material from Peptides Lab UK: KLOW for laboratory research (UK dispatch, batch certificate of analysis, research use only).
